Genetic Technologies Expands Operational Capacity in North America

Core Insights - Genetic Technologies Limited (GTG) has commenced testing operations in the U.S. for its geneType™ genetic risk assessment product series, marking a significant expansion in its service offerings [1][3] - The company has developed a suite of integrated genetic testing tools that assess individual risks for serious diseases, leveraging its pioneering work in polygenic risk scores (PRS) [2][4] - GTG's collaboration with Gene by Gene and Stayhealthy enhances its operational capacity and distribution network in North America, positioning the company for substantial growth [7][9] Company Overview - Genetic Technologies Limited is a leader in genomics-based tests, focusing on health, wellness, and serious diseases through its geneType and EasyDNA brands [4][11] - The company has developed a proprietary risk stratification platform over the past decade, integrating clinical and genetic risk to provide actionable outcomes for healthcare providers and individuals [4][12] - GTG's geneType tests are clinically validated and regulatory approved, with a focus on non-invasive, saliva-based assessments for various diseases [8][12] Strategic Partnerships - The partnership with Gene by Gene, a highly accredited genetic laboratory, allows GTG to process up to 25,000 tests per month, significantly increasing its operational capacity [7] - Stayhealthy's collaboration will broaden the reach of geneType's tests through employee health benefits and online pharmacy channels, targeting a consumer base of up to 1.5 million users [9] - Stayhealthy's extensive database of over 200 million U.S. email addresses positions it well to promote geneType's health risk assessments across North America [9]